Do analysts rate ATYR or LIAN?

aTyr Pharma currently has a consensus price target of $17.00, suggesting a potential upside of 3,491.80%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ATYR or LIAN?

aTyr Pharma has higher revenue and earnings than LianBio. aTyr Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 244.25 -$74.12M -$0.73 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is ATYR or LIAN more profitable?

LianBio's return on equity of -33.17% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% LianBio N/A -33.17% -30.19%

Do analysts rate HYPD or LIAN?

Hyperion DeFi currently has a consensus price target of $6.95, indicating a potential upside of 176.89%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Hyperion DeFi is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperion DeFi 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HYPD or LIAN more profitable?

LianBio's return on equity of -33.17% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% LianBio N/A -33.17% -30.19%

Do analysts prefer LIAN or ATHE?

Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 186.34%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, LIAN or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is LIAN or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Alterity Therapeutics N/A N/A N/A

Is LIAN or CPHI more profitable?

LianBio has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. LianBio's return on equity of -33.17% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% China Pharma -85.56% -63.93% -31.42%

Which has better valuation and earnings, or LIAN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio N/A N/A N/A N/A N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is or LIAN more profitable?

's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets N/A N/A N/A LianBio N/A -33.17% -30.19%

LianBio (LIAN) Competitors

$0.05 0.00 (-7.14%)

As of 07/24/2026

Compare

LIAN vs. ATYR, HYPD, ATHE, CPHI, and FTH

Should you buy LianBio stock or one of its competitors? MarketBeat compares LianBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LianBio include aTyr Pharma (ATYR), Hyperion DeFi (HYPD), Alterity Therapeutics (ATHE), China Pharma (CPHI), and Sensei Biotherapeutics (FTH). These companies are all part of the "pharmaceutical products" industry.

How does LianBio compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

LianBio's return on equity of -33.17% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
LianBio	N/A	-33.17%	-30.19%

aTyr Pharma has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

aTyr Pharma has higher revenue and earnings than LianBio. aTyr Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	244.25	-$74.12M	-$0.73	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, aTyr Pharma had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for aTyr Pharma and 0 mentions for LianBio. aTyr Pharma's average media sentiment score of 0.96 beat LianBio's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Positive
LianBio	Neutral

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

aTyr Pharma currently has a consensus price target of $17.00, suggesting a potential upside of 3,491.80%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

aTyr Pharma beats LianBio on 10 of the 15 factors compared between the two stocks.

How does LianBio compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Hyperion DeFi currently has a consensus price target of $6.95, indicating a potential upside of 176.89%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Hyperion DeFi is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hyperion DeFi had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Hyperion DeFi and 0 mentions for LianBio. Hyperion DeFi's average media sentiment score of 1.87 beat LianBio's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Very Positive
LianBio	Neutral

Hyperion DeFi has a beta of 2.49, meaning that its stock price is 149% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Hyperion DeFi has higher revenue and earnings than LianBio. Hyperion DeFi is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

LianBio's return on equity of -33.17% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
LianBio	N/A	-33.17%	-30.19%

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Hyperion DeFi beats LianBio on 8 of the 14 factors compared between the two stocks.

How does LianBio compare to Alterity Therapeutics?

LianBio (NASDAQ:LIAN) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Alterity Therapeutics had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Alterity Therapeutics and 0 mentions for LianBio. Alterity Therapeutics' average media sentiment score of 0.62 beat LianBio's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Alterity Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 186.34%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

74.8% of LianBio shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alterity Therapeutics' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats LianBio on 10 of the 11 factors compared between the two stocks.

How does LianBio compare to China Pharma?

LianBio (NASDAQ:LIAN) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

China Pharma has higher revenue and earnings than LianBio. China Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
China Pharma	$3.99M	15.43	-$3.08M	-$0.55	N/A

LianBio has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. LianBio's return on equity of -33.17% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
China Pharma	-85.56%	-63.93%	-31.42%

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 6.4% of China Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, China Pharma had 5 more articles in the media than LianBio. MarketBeat recorded 5 mentions for China Pharma and 0 mentions for LianBio. China Pharma's average media sentiment score of 0.28 beat LianBio's score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
China Pharma	Neutral

Summary

LianBio and China Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does LianBio compare to ?

(:) and LianBio (NASDAQ:LIAN) are related companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
	N/A	N/A	N/A	N/A	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, had 1156 more articles in the media than LianBio. MarketBeat recorded 1156 mentions for and 0 mentions for LianBio. 's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
	Neutral
LianBio	Neutral

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

Summary

beats LianBio on 3 of the 5 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.62M	$434.82M	$6.87B	$12.26B
Dividend Yield	N/A	3.90%	2.67%	9.79%
P/E Ratio	-0.06	3.16	27.14	23.64
Price / Sales	N/A	6,592.20	517.06	88.99
Price / Cash	N/A	13.13	50.54	59.64
Price / Book	0.02	83.70	10.28	6.07
Net Income	-$110.29M	-$96.07M	$3.60B	$331.99M
7 Day Performance	N/A	-0.66%	-1.27%	-0.63%
1 Month Performance	N/A	-1.07%	-0.37%	-2.00%
1 Year Performance	N/A	56.07%	18.30%	13.62%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.05 -7.1%	N/A	+3.7%	$5.62M	N/A	N/A	110
ATYR aTyr Pharma	3.5379 of 5 stars	$0.53 +9.9%	$17.00 +3,081.7%	-91.5%	$47.65M	$190K	N/A	53	Short Interest Decrease High Trading Volume
HYPD Hyperion DeFi	3.17 of 5 stars	$3.02 +2.0%	$6.95 +130.1%	-69.3%	$44.87M	$1.04M	N/A	40
ATHE Alterity Therapeutics	3.2783 of 5 stars	$4.99 -0.8%	$13.00 +160.5%	-20.1%	$44.60M	N/A	N/A	10	Gap Down
CPHI China Pharma	N/A	$1.10 +78.9%	N/A	-18.5%	$44.57M	$3.99M	N/A	250	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors

LIAN vs. ATYR, HYPD, ATHE, CPHI, and FTH

How does LianBio compare to aTyr Pharma?

Summary

How does LianBio compare to Hyperion DeFi?

Summary

How does LianBio compare to Alterity Therapeutics?

Summary

How does LianBio compare to China Pharma?

Summary

How does LianBio compare to ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LianBio (LIAN) Competitors

LIAN vs. ATYR, HYPD, ATHE, CPHI, and FTH

How does LianBio compare to aTyr Pharma?

Is ATYR or LIAN more profitable?

Which has more volatility and risk, ATYR or LIAN?

Which has stronger earnings and valuation, ATYR or LIAN?

Does the media refer more to ATYR or LIAN?

Do insiders & institutionals believe in ATYR or LIAN?

Do analysts rate ATYR or LIAN?

Summary

How does LianBio compare to Hyperion DeFi?

Do analysts rate HYPD or LIAN?

Does the media refer more to HYPD or LIAN?

Which has more volatility & risk, HYPD or LIAN?

Which has higher earnings and valuation, HYPD or LIAN?

Is HYPD or LIAN more profitable?

Do institutionals & insiders have more ownership in HYPD or LIAN?

Summary

How does LianBio compare to Alterity Therapeutics?

Which has more volatility & risk, LIAN or ATHE?

Does the media prefer LIAN or ATHE?

Which has stronger valuation & earnings, LIAN or ATHE?

Do analysts prefer LIAN or ATHE?

Do insiders & institutionals hold more shares of LIAN or ATHE?

Is LIAN or ATHE more profitable?

Summary

How does LianBio compare to China Pharma?

Which has more volatility and risk, LIAN or CPHI?

Which has preferable earnings and valuation, LIAN or CPHI?

Is LIAN or CPHI more profitable?

Do institutionals & insiders hold more shares of LIAN or CPHI?

Does the media prefer LIAN or CPHI?

Summary

How does LianBio compare to ?

Which has better valuation and earnings, or LIAN?

Does the media favor or LIAN?

Do insiders & institutionals hold more shares of or LIAN?

Is or LIAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools